Becton Dickinson Microbiology Systems licenses Alamar Biosciences technology:
This article was originally published in Clinica
Becton Dickinson Microbiology Systems is to acquire a semi- exclusive, worldwide licence to Alamar Biosciences' alamarBlue technology. Under a letter of intent signed by the two companies on May 8th, Alamar would receive up to $3.5 million and undisclosed royalties on product sales incorporating the technology. Alamar, which is to merge with AccuMed to form AccuMed International (see Clinica No 652, p 15), says the agreement with Becton Dickinson will double its own distribution capabilities. AccuMed International will retain rights to use the alamarBlue technology in any of its own commercial products.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.